OMCLHealthcare · Health Information ServicesThe 8 Wall Street analysts covering Omnicell, Inc. hold a median 12-month price target of $55 — +39.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Omnicell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Momentum (58): The shares have been drifting down relative to others.
Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OMCL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | Freedom Capital Markets | Maintains | Buy | — |
| 30 Oct 2026 | Freedom Capital Markets | Maintains | Buy | $60 → $55 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | $55 → $45 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 31 July 2026 | Keybanc | Maintains | Overweight | $70 → $65 |
| 31 July 2026 | Keybanc | Maintains | Overweight | — |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | $55 → $50 |
| 29 Apr 2026 | Keybanc | Maintains | Overweight | $60 → $70 |
| 29 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 23 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 23 Apr 2026 | Wells Fargo | Maintains | Overweight | $52 → $55 |
| 6 Feb 2026 | Piper Sandler | Reiterates | Overweight | — |
| 2 Feb 2026 | Benchmark | Maintains | Buy | — |
| 8 Jan 2026 | Keybanc | Upgrade | Overweight | — |
| 5 Jan 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Dec 2025 | B of A Securities | Maintains | Neutral | — |
| 9 Dec 2025 | Benchmark | Maintains | Buy | — |
| 31 Oct 2025 | Benchmark | Maintains | Buy | — |
| 11 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OMCL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Omnicell, Inc. returned +14.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 62% of US stocks
Cheaper than 63% of US stocks
Cheaper than 23% of US stocks
Higher than 26% of US stocks
Higher than 84% of US stocks
Higher than 61% of US stocks
Higher than 54% of US stocks
Higher than 56% of US stocks
Higher than 50% of US stocks
Higher than 60% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Omnicell, Inc. has a market value of $1.6B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter shrank 0.9% year on year.
Net income over the same four quarters: $39.1M, a 3.1% net margin.
Diluted earnings per share, trailing twelve months: $0.84.
Free cash flow in the twelve months to 30 June 2026: $126.8M.
Trailing P/E: 36.7×; forward P/E: 17.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Omnicell, Inc. employs 3,580 people — $348K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Omnicell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research’s headline calls Omnicell a top value stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks, but provides no specific score or supporting details about Omnicell.
Why it matters — OMCL watchers may note the favorable value-stock framing, while the excerpt offers little detail to assess the claim.
Omnicell held its third-quarter 2026 financial results call on October 29, 2026. The excerpt lists company executives and analysts who participated but provides no financial results or discussion details.
Why it matters — OMCL watchers can note the earnings call took place, but this excerpt contains no information about the company’s performance or outlook.
Omnicell reported third-quarter 2026 revenue and non-GAAP EBITDA above the high end of prior guidance. Executives said shipments of Titan XT automated dispensing hardware are being prepared, and OmniSphere cloud platform availability remains on track for the first half of 2027.
Why it matters — The update provides OMCL watchers information on results relative to guidance and the timing of two product initiatives.
The article says Omnicell’s Q3 2026 top- and bottom-line results offer one view of its performance for the quarter ended September 2026, and points readers to key metrics compared with Wall Street estimates and year-ago values.
Why it matters — Those comparisons provide additional context for assessing Omnicell’s quarterly performance beyond its headline results.
Omnicell reported quarterly earnings of $0.58 per share, above the Zacks Consensus Estimate of $0.42. Earnings were $0.51 per share in the year-ago quarter.
Why it matters — The results give OMCL watchers an update on quarterly earnings relative to analyst consensus and the prior-year period.
The 8 Wall Street analysts covering Omnicell, Inc. have a median 12-month price target of $55, with estimates ranging from $50 to $68. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Omnicell, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omnicell, Inc. 98 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Omnicell, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +39.6% from the last close, and Ticker Nerd's factor model ranks Omnicell, Inc. 98 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Omnicell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $68 over the next 12 months.
Omnicell, Inc. returned +14.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings.
The most recent item we track (Zacks Investment Research, 3 Nov 2026): "Why Omnicell (OMCL) is a Top Value Stock for the Long-Term". Zacks Investment Research’s headline calls Omnicell a top value stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks, but provides no specific score or supporting details about Omnicell.
Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings. Omnicell’s portfolio includes automated dispensing systems, central pharmacy automation, robotic dispensing, IV compounding, inventory management software, and point-of-care solutions designed to streamline medication workflows and support safer medication handling. The company also offers patient engagement and medication adherence tools through its EnlivenHealth brand, helping pharmacies and providers manage prescriptions, packaging, and communication more efficiently. Omnicell’s products and services are used across inpatient, outpatient, post-acute, and retail environments, where they support clinical teams with automation, analytics, and workflow integration. The company plays a notable role in healthcare operations by helping organizations improve medication management across the care continuum.
CEO Mr. Randall A. Lipps · 3,580 employees · United States · https://www.omnicell.com
